⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
prnewswire.com
IOVA
MRK
LLY
JNJ
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
prnewswire.com
JNJ
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
prnewswire.com
JNJ
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
prnewswire.com
JNJ
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
prnewswire.com
JNJ
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
prnewswire.com
JNJ
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
prnewswire.com
JNJ
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
businesswire.com
JNJ
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
businesswire.com
JNJ
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
businesswire.com
JNJ